466 related articles for article (PubMed ID: 27735912)
21. Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy.
Janzon M; James S; Cannon CP; Storey RF; Mellström C; Nicolau JC; Wallentin L; Henriksson M
Heart; 2015 Jan; 101(2):119-25. PubMed ID: 25227704
[TBL] [Abstract][Full Text] [Related]
22. Coronary artery bypass grafting-related bleeding complications in real-life acute coronary syndrome patients treated with clopidogrel or ticagrelor.
Hansson EC; Rexius H; Dellborg M; Albertsson P; Jeppsson A
Eur J Cardiothorac Surg; 2014 Oct; 46(4):699-705; discussion 705. PubMed ID: 24482383
[TBL] [Abstract][Full Text] [Related]
23. A Cost-Effectiveness Analysis of Clopidogrel for Patients with Non-ST-Segment Elevation Acute Coronary Syndrome in China.
Cui M; Tu CC; Chen EZ; Wang XL; Tan SC; Chen C
Adv Ther; 2016 Sep; 33(9):1600-11. PubMed ID: 27397588
[TBL] [Abstract][Full Text] [Related]
24. [Long-term cost-effectiveness of ticagrelor versus clopidogrel in acute coronary syndrome in Spain].
Molina-Cuadrado E; Mateo-Carrasco H; Nieto-Guindo P; Rodríguez-Gómez P
Farm Hosp; 2014 Jul; 38(4):266-75. PubMed ID: 25137159
[TBL] [Abstract][Full Text] [Related]
25. Comparison of 6-Month Costs Between Oral Antiplatelet Agents Following Acute Coronary Syndrome.
Kim K; Lee TA; Touchette DR; DiDomenico RJ; Ardati AK; Walton SM
J Manag Care Spec Pharm; 2018 Aug; 24(8):800-812. PubMed ID: 30058986
[TBL] [Abstract][Full Text] [Related]
26. The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis.
Rogowski W; Burch J; Palmer S; Craigs C; Golder S; Woolacott N
Health Technol Assess; 2009 Jun; 13(31):iii-iv, ix-xi, 1-77. PubMed ID: 19573471
[TBL] [Abstract][Full Text] [Related]
27. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial.
Held C; Asenblad N; Bassand JP; Becker RC; Cannon CP; Claeys MJ; Harrington RA; Horrow J; Husted S; James SK; Mahaffey KW; Nicolau JC; Scirica BM; Storey RF; Vintila M; Ycas J; Wallentin L
J Am Coll Cardiol; 2011 Feb; 57(6):672-84. PubMed ID: 21194870
[TBL] [Abstract][Full Text] [Related]
28. Health Economic Analysis of Antiplatelet Therapy for Acute Coronary Syndromes in the Context of Five Eastern Asian Countries.
Wu B; Tobe RG; Liu Y; He B
Clin Drug Investig; 2018 Jul; 38(7):621-630. PubMed ID: 29713921
[TBL] [Abstract][Full Text] [Related]
29. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
Kourlaba G; Fragoulakis V; Maniadakis N
Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992
[TBL] [Abstract][Full Text] [Related]
30. Coronary artery bypass grafting-related bleeding complications in patients treated with dual antiplatelet treatment.
Tomšič A; Schotborgh MA; Manshanden JS; Li WW; de Mol BA
Eur J Cardiothorac Surg; 2016 Nov; 50(5):849-856. PubMed ID: 27174551
[TBL] [Abstract][Full Text] [Related]
31. Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy.
Tanguay JF; Bell AD; Ackman ML; Bauer RD; Cartier R; Chan WS; Douketis J; Roussin A; Schnell G; Verma S; Wong G; Mehta SR;
Can J Cardiol; 2013 Nov; 29(11):1334-45. PubMed ID: 23978596
[TBL] [Abstract][Full Text] [Related]
32. Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study.
Kohli P; Wallentin L; Reyes E; Horrow J; Husted S; Angiolillo DJ; Ardissino D; Maurer G; Morais J; Nicolau JC; Oto A; Storey RF; James SK; Cannon CP
Circulation; 2013 Feb; 127(6):673-80. PubMed ID: 23277305
[TBL] [Abstract][Full Text] [Related]
33. Evaluating the risk-benefit profile of the direct-acting P2Y(12) inhibitor ticagrelor in acute coronary syndromes.
Husted S
Postgrad Med; 2011 Nov; 123(6):79-90. PubMed ID: 22104457
[TBL] [Abstract][Full Text] [Related]
34. Parathyroid Hormone Levels and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Acetylsalicylic Acid and Clopidogrel or Ticagrelor.
Verdoia M; Pergolini P; Rolla R; Nardin M; Barbieri L; Schaffer A; Bellomo G; Marino P; Suryapranata H; De Luca G;
Cardiovasc Ther; 2016 Aug; 34(4):209-15. PubMed ID: 27086085
[TBL] [Abstract][Full Text] [Related]
35. Administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome.
Caiazzo G; De Rosa S; Torella D; Spaccarotella C; Mongiardo A; Giampà S; Micieli M; Palella E; Gulletta E; Indolfi C
Circ Cardiovasc Interv; 2014 Feb; 7(1):104-12. PubMed ID: 24449597
[TBL] [Abstract][Full Text] [Related]
36. A randomized, parallel group, double-blind study of ticagrelor compared with aspirin for prevention of vascular events in patients undergoing coronary artery bypass graft operation: Rationale and design of the Ticagrelor in CABG (TiCAB) trial: An Investigator-Initiated trial.
de Waha A; Sandner S; von Scheidt M; Boening A; Koch-Buettner K; Hammel D; Hambrecht R; Danner BC; Schöndube FA; Goerlach G; Fischlein T; Schmoeckel M; Oberhoffer M; Schulz R; Walther T; Ziegelhöffer T; Knosalla C; Schönrath F; Beyersdorf F; Siepe M; Attmann T; Misfeld M; Mohr FW; Sievers HH; Joost A; Putman LM; Laufer G; Hamm C; Zeymer U; Kastrati A; Radke PW; Lange R; Cremer J; Schunkert H
Am Heart J; 2016 Sep; 179():69-76. PubMed ID: 27595681
[TBL] [Abstract][Full Text] [Related]
37. Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial.
Patel MR; Becker RC; Wojdyla DM; Emanuelsson H; Hiatt WR; Horrow J; Husted S; Mahaffey KW; Steg PG; Storey RF; Wallentin L; James SK
Eur J Prev Cardiol; 2015 Jun; 22(6):734-42. PubMed ID: 24830710
[TBL] [Abstract][Full Text] [Related]
38. Cost-Effectiveness Analysis of Ticagrelor and Prasugrel for the Treatment of Acute Coronary Syndrome.
Zhao YJ; Khoo AL; Lin L; Teng M; Wu TS; Chan MY; Lim BP
Value Health Reg Issues; 2016 May; 9():22-27. PubMed ID: 27881255
[TBL] [Abstract][Full Text] [Related]
39. Uric acid and high-residual platelet reactivity in patients treated with clopidogrel or ticagrelor.
Barbieri L; Verdoia M; Pergolini P; Nardin M; Rolla R; Marino P; Bellomo G; Suryapranata H; De Luca G;
Nutr Metab Cardiovasc Dis; 2016 Apr; 26(4):352-8. PubMed ID: 26857781
[TBL] [Abstract][Full Text] [Related]
40. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
